

Araceli GarcÃ-a-MartÃ-nez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2898867/publications.pdf>

Version: 2024-02-01

17
papers

200
citations

1040056

9
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

455
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative clinical, radiological and molecular analysis for predicting remission and recurrence of Cushing's disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	3
2	Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors. <i>Human Pathology</i> , 2021, 110, 20-30.	2.0	6
3	Hedgehog gene expression patterns among intrinsic subtypes of breast cancer: Prognostic relevance. <i>Pathology Research and Practice</i> , 2021, 223, 153478.	2.3	3
4	Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 1838.	2.4	5
5	Increased E2F1 mRNA and miR-17-5p Expression Is Correlated to Invasiveness and Proliferation of Pituitary Neuroendocrine Tumours. <i>Diagnostics</i> , 2020, 10, 227.	2.6	10
6	Can the molecular typing of the specific adenohypophyseal hormone genes be useful in the management of pituitary neuroendocrine tumours?. <i>Endocrinología, Diabetes Y Nutrición</i> , 2019, 66, 395-397.	0.3	1
7	Can the molecular typing of the specific adenohypophyseal hormone genes be useful in the management of pituitary neuroendocrine tumours?. <i>Endocrinología Diabetes Y Nutrición (English Ed)</i> , 2019, 66, 395-397.	0.2	0
8	DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1272-1282.	3.6	21
9	How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?. <i>Cancers</i> , 2019, 11, 1990.	3.7	12
10	Silent somatotropinomas. <i>Minerva Endocrinologica</i> , 2019, 44, 137-142.	1.8	7
11	Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. <i>Minerva Endocrinologica</i> , 2019, 44, 109-128.	1.8	23
12	Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?. <i>PLoS ONE</i> , 2018, 13, e0198877.	2.5	13
13	CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 81-90.	2.8	4
14	Lack of cytomegalovirus detection in human glioma. <i>Virology Journal</i> , 2017, 14, 216.	3.4	24
15	KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia. <i>PLoS ONE</i> , 2017, 12, e0184937.	2.5	26
16	Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3 + Tregs. <i>Experimental and Molecular Pathology</i> , 2016, 100, 460-468.	2.1	15
17	FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 465-474.	2.5	27